Denali Therapeutics Inc
NASDAQ:DNLI
Denali Therapeutics Inc
Net Income
Denali Therapeutics Inc
Net Income Peer Comparison
Competitive Net Income Analysis
Latest Figures & CAGR of Competitors
Company | Net Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Denali Therapeutics Inc
NASDAQ:DNLI
|
Net Income
-$137.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-22%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Net Income
$6B
|
CAGR 3-Years
5%
|
CAGR 5-Years
2%
|
CAGR 10-Years
4%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Net Income
-$959m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Amgen Inc
NASDAQ:AMGN
|
Net Income
$3.8B
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-2%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Net Income
$4B
|
CAGR 3-Years
13%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Net Income
$3.9B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
10%
|
CAGR 10-Years
26%
|
See Also
What is Denali Therapeutics Inc's Net Income?
Net Income
-137.3m
USD
Based on the financial report for Mar 31, 2024, Denali Therapeutics Inc's Net Income amounts to -137.3m USD.
What is Denali Therapeutics Inc's Net Income growth rate?
Net Income CAGR 5Y
-22%
Over the last year, the Net Income growth was 63%.